Compare CRSP & OGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | OGS |
|---|---|---|
| Founded | 2013 | 1906 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 2016 | 2013 |
| Metric | CRSP | OGS |
|---|---|---|
| Price | $49.80 | $77.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $70.29 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.7M | 605.3K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 3.10% |
| EPS Growth | N/A | ★ 11.76 |
| EPS | N/A | ★ 2.04 |
| Revenue | $289,590,000.00 | ★ $2,578,005,000.00 |
| Revenue This Year | $807.72 | $12.51 |
| Revenue Next Year | $172.52 | N/A |
| P/E Ratio | ★ N/A | $37.30 |
| Revenue Growth | ★ 9169.85 | 42.54 |
| 52 Week Low | $40.76 | $70.87 |
| 52 Week High | $78.48 | $90.78 |
| Indicator | CRSP | OGS |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 41.13 |
| Support Level | $46.15 | $75.45 |
| Resistance Level | $59.61 | $79.30 |
| Average True Range (ATR) | 2.91 | 1.74 |
| MACD | -0.35 | 0.05 |
| Stochastic Oscillator | 9.92 | 32.61 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. It operates in one reportable business segment: regulated public utilities that deliver natural gas to residential, commercial, and transportation customers.